BofA keeps a Buy rating on Catalyst Pharmaceuticals (CPRX) with a $30 price target following the announcement of a Firdapse patent settlement with a key generic challenger Teva (TEVA). Teva was ...

12:25 EST Catalyst Pharmaceuticals (CPRX) trading halted, news pending Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for ...

Catalyst Energy Infrastructure Fund earns a Below Average Process Pillar rating. The process is bolstered by the fund's impressive long-term risk-adjusted performance. This can be seen in its five ...

It wasn't just fact-checking that Meta scrapped from its platforms as it prepares for the second Trump administration. The social media giant has also loosened its rules around hate speech and ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In the 2024 election, US Catholics voted in large numbers for Donald Trump. It’s far from inevitable that Catholics find their home on the Right — the church has long promoted radically egalitarian ...

Early US elites drafted the Constitution to check democratic uprisings that threatened the power of the ruling class. The ...

After hours: January 8 at 6:14:47 PM EST Loading Chart for HCAT ...

One of the crucial things in every relationship is trust; without it, Chekhov wrote, ‘life becomes impossible’. But in our ...

Forbes does not accept payment for placement on lists.

Berkshire Hathaway Inc. Cl A-2.20% $974.44B Berkshire Hathaway Inc. Cl B-2.03% $974.44B ...